Articles From: Actuate Signs Agreement to be Acquired by OpenText to Adams Express Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment


Actuate Corporation (NASDAQ:BIRT), The BIRT Company™ and the leader in personalized analytics and insights, today announced that it has entered into an agreement to be acquired by OpenText.
Sign-up for Actuate Signs Agreement to be Acquired by OpenText investment picks
Actuate Corporation (NASDAQ: BIRT) – the leader in embedded analytics, today announced the lineup of keynote speakers and technically focused breakout sessions for its annual customer conference, Data Driven Summit 2014 , taking place in the following cities: Santa Clara on Nov.
Sign-up for Actuate to Address the Future of Embedded Analytics at Data Driven Summit 2014 investment picks
ATLANTA, Jan.
Sign-up for Acuity Brands Reports Record First Quarter Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G025318-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/3/11G025318/Acura_Pharmaceuticals,_Inc.-6733629489.jpg PALATINE, IL--(Marketwired - November 03, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014.
Sign-up for Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G029778-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/7/11G029778/Acura_Pharmaceuticals,_Inc.-6733629489.jpg PALATINE, IL--(Marketwired - January 08, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement") with Egalet US, Inc. and Egalet Ltd.
Sign-up for Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G027946-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/5/11G027946/Acura_Pharmaceuticals,_Inc.-6733629489.jpg PALATINE, ILL--(Marketwired - December 08, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company has been issued U.S. Patent No.
Sign-up for Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G024813-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/10/28/11G024813/Acura_Pharmaceuticals,_Inc.-6733629489.jpg PALATINE, IL--(Marketwired - October 28, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on Monday, November 3, 2014.
Sign-up for Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014 investment picks
Acxiom® (Nasdaq: ACXM), an enterprise data, analytics and software-as-a-service Company, today announced that Nada Stirratt will step down as Chief Revenue Officer to pursue other opportunities.
Sign-up for Acxiom Announces Resignation of Chief Revenue Officer investment picks
Acxiom® (Nasdaq: ACXM), an enterprise data, analytics and software-as-a-service Company, today announced financial results for its second quarter ended September 30, 2014.
Sign-up for Acxiom Announces Second Quarter Results investment picks
Acxiom® (NASDAQ: ACXM), an enterprise data, analytics and software-as-a-service company, today announced three strategic hires, further strengthening its executive bench.
Sign-up for Acxiom Boosts Key Strategic Offerings investment picks
Acxiom® (Nasdaq: ACXM), an enterprise data, analytics and software-as-a-service Company, today announced that its Board of Directors voted to extend the duration of the Company's existing share repurchase program for an additional year, through November 12, 2015.
Sign-up for Acxiom Extends Share Repurchase Program investment picks
Acxiom® (NASDAQ:ACXM), an enterprise data, analytics and software-as-a-service company, today announced it has joined the Salesforce Analytics Cloud Ecosystem to provide consumer recognition, data assets and value-added analytic insights to users, improving critical decision processes, and driving improvement in overall business results.
Sign-up for Acxiom Joins New Salesforce Analytics Cloud Ecosystem to Drive Consumer Data into the Heart of Business Decision-Making investment picks
Qlik® (NASDAQ: QLIK), a leader in data discovery, today announced that executive producer and co-star of Discovery Channel’s hit television show “MythBusters” Adam Savage, has joined the keynote lineup at the 2014 Qlik World Conference , which takes place November 17 – 20 at the Rosen Shingle Creek in Orlando.
Sign-up for Adam Savage Joins Keynote Lineup at Qlik World Conference 2014 investment picks
EMERYVILLE, Calif., Dec.
Sign-up for Adamas Pharmaceuticals Issued Six Additional U.S. Patents investment picks
EMERYVILLE, Calif., Jan.
Sign-up for Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers investment picks
EMERYVILLE, Calif., Jan.
Sign-up for Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis investment picks
EMERYVILLE, Calif., Nov.
Sign-up for Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference investment picks
EMERYVILLE, Calif., Nov.
Sign-up for Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference investment picks
EMERYVILLE, Calif., Nov.
Sign-up for Adamas Reports Third Quarter 2014 Financial Results investment picks
Shares of Adamas Pharmaceuticals (ADMS) shot up 16% in premarket trade Wednesday, after the company and development partner Actavis (ACT) said the new drug application for Namzaric for the treatment of Alzheimer's-type dementia was approved by the U.S. Food and Drug Administration.
Sign-up for Adamas' stock soars after dementia treatment approval investment picks
SAN DIEGO, Jan.
Sign-up for Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock investment picks
SAN DIEGO, Dec.
Sign-up for Adamis Pharmaceuticals to Present at Two Upcoming Conferences investment picks
2015/1/21
BALTIMORE , Jan.
Sign-up for Adams Express Fund Announces Management Changes investment picks
BALTIMORE , Jan.
Sign-up for Adams Express Fund Declares Dividend investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Actuate Signs Agreement to be Acquired by OpenText to Adams Express Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent